Alnylam Pharmaceuticals
$219.72Change from previous close: −4.96%Absolute change: −$11.46
At a glance
- Revenue growth
- +65.19%
- 2025 vs 2024
- Net margin
- 8.4%
- 2024: -12.4%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | 3,714 | 2,248 | 1,828 | 1,037 |
| Cost of revenue | 682 | 323 | 310 | 169 |
| Gross profit | 3,032 | 1,925 | 1,518 | 869 |
| Selling, general and administrative | 1,211 | 976 | 796 | 771 |
| Research and development | 1,320 | 1,126 | 1,004 | 883 |
| Operating income | 502 | -177 | -282 | -785 |
| EBIT | 576 | -236 | -312 | -971 |
| EBITDA | 631 | -179 | -258 | -927 |
| Interest expense | 253 | 142 | 121 | 156 |
| Pre-tax income | 323 | -377 | -434 | -1,127 |
| Income tax | 9.4 | -99.2 | 6.7 | 4.2 |
| Net income | 314 | -278 | -440 | -1,131 |
| Net income to common shareholders | 314 | -278 | -440 | -1,131 |
| Basic EPS | 2.39 | -2.18 | -3.52 | -9.30 |
| Diluted EPS | 2.33 | -2.18 | -3.52 | -9.30 |
| Average shares (basic) | 131 | 128 | 125 | 122 |
| Average shares (diluted) | 135 | 128 | 125 | 122 |